Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88271071 |
LAW OFFICE ASSIGNED |
LAW OFFICE 101 |
MARK SECTION |
MARK |
SELQUONA (see, http://uspto.report/TM/88271071/mark.png) |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
SELQUONA |
OWNER SECTION (current) |
NAME |
Glaxo Group Limited |
MAILING ADDRESS |
980 Great West Road |
CITY |
Brentford, Middlesex |
ZIP/POSTAL CODE |
TW89GS |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United Kingdom |
OWNER SECTION (proposed) |
NAME |
Glaxo Group Limited |
MAILING ADDRESS |
980 Great West Road |
CITY |
Brentford, Middlesex |
ZIP/POSTAL CODE |
TW89GS |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United Kingdom |
EMAIL |
XXXX |
ATTORNEY INFORMATION (current) |
NAME |
Merilee J. Arevalo |
ATTORNEY BAR MEMBERSHIP NUMBER |
XXX |
YEAR OF ADMISSION |
XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY |
XX |
FIRM NAME |
GSK |
INTERNAL ADDRESS |
LBP, 5.5A |
STREET |
5 MOORE DRIVE |
CITY |
RESEARCH TRIANGLE PARK |
STATE |
North Carolina |
POSTAL CODE |
27709-3398 |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
PHONE |
919-323-6951 |
FAX |
919-315-3023 |
EMAIL |
trademarks@gsk.com |
DOCKET/REFERENCE NUMBER |
82766966 |
ATTORNEY INFORMATION (proposed) |
NAME |
Merilee J. Arevalo |
ATTORNEY BAR MEMBERSHIP NUMBER |
XXX |
YEAR OF ADMISSION |
XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY |
XX |
FIRM NAME |
GSK |
INTERNAL ADDRESS |
LBP, 5.5A |
STREET |
5 MOORE DRIVE |
CITY |
RESEARCH TRIANGLE PARK |
STATE |
North Carolina |
POSTAL CODE |
27709-3398 |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
PHONE |
919-315-8204 |
FAX |
919-315-3023 |
EMAIL |
trademarks@gsk.com |
DOCKET/REFERENCE NUMBER |
82766966 |
OTHER APPOINTED ATTORNEY |
Hanes, Christopher, M., Dixon, Terence, A., Farber, Michele, A. |
CORRESPONDENCE INFORMATION (current) |
NAME |
MERILEE J. AREVALO |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
trademarks@gsk.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
DOCKET/REFERENCE NUMBER |
82766966 |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
Merilee J. Arevalo |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
trademarks@gsk.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
DOCKET/REFERENCE NUMBER |
82766966 |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the
treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral,
metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal,
hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
2 |
ONGOING EFFORT |
product or service research or development ; manufacturing activities ; steps to obtain required governmental approval |
ALLOWANCE MAIL DATE |
07/09/2019 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
TOTAL AMOUNT |
125 |
SIGNATURE SECTION |
SIGNATURE |
/Merilee J. Arevalo/ |
SIGNATORY'S NAME |
Arevalo, Merilee, J. |
SIGNATORY'S POSITION |
Trademark Counsel, GSK, NJ and PA bar member |
DATE SIGNED |
03/03/2020 |
SIGNATORY'S PHONE NUMBER |
919-315-8204 |
FILING INFORMATION |
SUBMIT DATE |
Wed Mar 04 10:55:01 ET 2020 |
TEAS STAMP |
USPTO/ESU-XXX.XX.XX.X-202
00304105501382196-8827107
1-710af2665ac2e2685f19c9c
8219ce64b6defc3943ffffdff
ad8d97fa21f695db6a-DA-550
04643-2020030311111148684
2 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: SELQUONA (see, http://uspto.report/TM/88271071/mark.png)
SERIAL NUMBER: 88271071
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Glaxo Group Limited, having an address of
980 Great West Road
Brentford, Middlesex, TW89GS
United Kingdom
Proposed: Glaxo Group Limited, having an address of
980 Great West Road
Brentford, Middlesex, TW89GS
United Kingdom
Phone:
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 07/09/2019.
For International Class 005:
Current identification: Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases,
blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal,
cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and
immune system related diseases and disorders; Vaccines
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development ; manufacturing activities ; steps to obtain required governmental approval
The applicant's current Attorney Information:
Merilee J. Arevalo GSK
LBP, 5.5A
5 MOORE DRIVE
RESEARCH TRIANGLE PARK, North Carolina 27709-3398
United States
Phone: 919-323-6951
Fax: 919-315-3023
The docket/reference number is 82766966
Email: trademarks@gsk.com
The applicant's proposed Attorney Information:
Merilee J. Arevalo GSK
LBP, 5.5A
5 MOORE DRIVE
RESEARCH TRIANGLE PARK, North Carolina 27709-3398
United States
Phone: 919-315-8204
Fax: 919-315-3023
The docket/reference number is 82766966
Email: trademarks@gsk.com
Correspondence Information (current):
MERILEE J. AREVALO
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gsk.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
Correspondence Information (proposed):
Merilee J. Arevalo
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gsk.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /Merilee J. Arevalo/ Date Signed: 03/03/2020
Signatory's Name: Arevalo, Merilee, J.
Signatory's Position: Trademark Counsel, GSK, NJ and PA bar member
Signatory's Phone: 919-315-8204
Mailing Address:
GSK
LBP, 5.5A
5 MOORE DRIVE
RESEARCH TRIANGLE PARK, North Carolina 27709-3398
RAM Sale Number: 88271071
RAM Accounting Date: 03/04/2020
Serial Number: 88271071
Internet Transmission Date: Wed Mar 04 10:55:01 ET 2020
TEAS Stamp: USPTO/ESU-XXX.XX.XX.X-202003041055013821
96-88271071-710af2665ac2e2685f19c9c8219c
e64b6defc3943ffffdffad8d97fa21f695db6a-D
A-55004643-20200303111111486842